Across TCGA pan-cancer cohorts, MIR1827 RNA is linked to patient survival in 15 of 34 cancer types, making it the most broadly survival-associated MIR1827 data layer.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher MIR1827 RNA is associated with better overall survival. In most high-consensus cancer types, elevated MIR1827 expression acts as an unfavorable survival marker, although some lineages such as STAD and LUAD show a favorable association.

STAD, MESO, and BLCA are the cancer types where MIR1827 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.766	0.626	<.001	78	view →
MESO	OS	Tertile	III,IV	0.310	0.605	<.001	63	view →
BLCA	DFS	Tertile	IV	0.245	0.479	.008	51	view →
LUAD	DFS	Tertile	III,IV	0.817	0.458	.018	27	view →
ACC	DFS	Tertile	III,IV	0.010	0.364	<.001	27	view →
GBM	OS	Tertile	All	0.111	0.418	.003	18	view →
READ	DFS	Tertile	III,IV	0.255	0.757	.008	18	view →
LIHC	OS	Tertile	All	0.219	0.510	.003	18	view →
ESCA	DFS	Median	III,IV	0.446	0.255	.016	17	view →
LAML	DFS	Median	All	0.533	0.270	.015	16	view →
LGG	OS	Tertile	All	0.263	0.457	.002	15	view →
HNSC	OS	Tertile	II,III,IV	0.239	0.604	.031	9	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 15 lineages.

Exploration

Same gene, other analysis: MIR1827 tumor-vs-normal RNA expression · all MIR1827 data types